Journal article icon

Journal article

Basophils promote barrier dysfunction and resolution in the atopic skin

Abstract:

Background The type 2 cytokines IL-4 and IL-13 promote not only atopic dermatitis (AD) but also the resolution of inflammation. How type 2 cytokines participate in the resolution of AD is poorly known.

Objective Our aim was to determine the mechanisms and cell types governing skin inflammation, barrier dysfunction, and resolution of inflammation in a model of AD.

Methods Mice that exhibit expression of IL-4, IL-13, and MCPT8 or that could be depleted of basophils or eosinophils, be deficient in IL-4 or MHC class II molecules, or have basophils lacking macrophage colony-stimulating factor (M-CSF) were treated with calcipotriol (MC903) as an acute model of AD. Kinetics of the disease; keratinocyte differentiation; and leukocyte accumulation, phenotype, function, and cytokine production were measured by transepidermal water loss, histopathology, molecular biology, or unbiased analysis of spectral flow cytometry.

Results In this model of AD, basophils were activated systemically and were the initial and main source of IL-4 in the skin. Basophils and IL-4 promoted epidermal hyperplasia and skin barrier dysfunction by acting on keratinocyte differentiation during inflammation. Basophils, IL-4, and basophil-derived M-CSF inhibited the accumulation of proinflammatory cells in the skin while promoting the expansion and function of proresolution M2-like macrophages and the expression of probarrier genes. Basophils kept their proresolution properties during AD resolution.

Conclusion Basophils can display both beneficial and detrimental type 2 functions simultaneously during atopic inflammation.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1016/j.jaci.2021.02.018

Authors

More by this author
Role:
Author
ORCID:
0000-0001-7036-0763
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Role:
Author
ORCID:
0000-0002-2505-5222
More by this author
Role:
Author
et al.


Publisher:
Elsevier
Journal:
Journal of Allergy and Clinical Immunology More from this journal
Volume:
148
Issue:
3
Pages:
799-812
Publication date:
2021-03-01
Acceptance date:
2021-02-12
DOI:
EISSN:
1097-6825
ISSN:
0091-6749
Pmid:
33662369


Language:
English
Keywords:
Pubs id:
1327739
Local pid:
pubs:1327739
Deposit date:
2023-02-07
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP